Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

A meta-analysis of wenxin granule and metoprolol for the treatment of coronary heart disease and arrhythmia

View through CrossRef
Background: This meta-analysis aimed to systematically and comprehensively assess the effectiveness and safety of wenxin granule (WXG) and metoprolol in the treatment of elderly patients with coronary heart disease (CHD) and arrhythmia. Methods: We searched the electronic databases of the Cochrane Library, PUBMED, EMBASE, CNKI, Wangfang, and CBM from initiation to May 1, 2022, and selected a set of clinical indicators for WXG and metoprolol for CHD and arrhythmia. The methodological quality of the included studies was analyzed using the Cochrane risk-of-bias tool. Data were pooled using a fixed-effects or random-effects model, and a meta-analysis was conducted. Results: Eight randomized controlled trials involving 722 patients with CHD and arrhythmia were included. Our findings showed that WXG and metoprolol showed better effects than metoprolol alone on electrocardiogram change (odds ratio [OR] = 7.21, 95% confidence interval [CI] [1.48, 35.07]), clinical symptom improvement (OR = 5.83, 95% CI [1.52, 22.35]), overall clinical effect (OR = 5.51, 95% CI [2.65, 11.44], P < .001), atrial premature beat (mean difference [MD] = −109.85, 95% CI [−171.25, −48.46], P < .001), ventricular premature beat (MD = −195.43, 95% CI [−334.09, −56.77], P < .001), borderline premature beat (MD = −42.92, 95% CI [−77.18, −8.67], P = .01), short-burst ventricular tachycardia (MD = −35.98, 95% CI [−39.66, −32.30], P < .001), ST segment reduction (MD = −0.47, 95% CI [−0.54, −0.40], P < .001), ST segment decrease duration (MD = −0.76, 95% CI [−0.95, −0.57], P < .001). However, no significant differences were observed in adverse reactions (OR = 0.54, 95% CI [0.27, 1.09], P = .09). Conclusion: Compared to metoprolol alone, WXG and metoprolol can more effectively manage patients with CHD and arrhythmia. However, additional large-scale, multicenter, rigorous, and high-quality randomized controlled trials are warranted to verify the present findings.
Ovid Technologies (Wolters Kluwer Health)
Title: A meta-analysis of wenxin granule and metoprolol for the treatment of coronary heart disease and arrhythmia
Description:
Background: This meta-analysis aimed to systematically and comprehensively assess the effectiveness and safety of wenxin granule (WXG) and metoprolol in the treatment of elderly patients with coronary heart disease (CHD) and arrhythmia.
Methods: We searched the electronic databases of the Cochrane Library, PUBMED, EMBASE, CNKI, Wangfang, and CBM from initiation to May 1, 2022, and selected a set of clinical indicators for WXG and metoprolol for CHD and arrhythmia.
The methodological quality of the included studies was analyzed using the Cochrane risk-of-bias tool.
Data were pooled using a fixed-effects or random-effects model, and a meta-analysis was conducted.
Results: Eight randomized controlled trials involving 722 patients with CHD and arrhythmia were included.
Our findings showed that WXG and metoprolol showed better effects than metoprolol alone on electrocardiogram change (odds ratio [OR] = 7.
21, 95% confidence interval [CI] [1.
48, 35.
07]), clinical symptom improvement (OR = 5.
83, 95% CI [1.
52, 22.
35]), overall clinical effect (OR = 5.
51, 95% CI [2.
65, 11.
44], P < .
001), atrial premature beat (mean difference [MD] = −109.
85, 95% CI [−171.
25, −48.
46], P < .
001), ventricular premature beat (MD = −195.
43, 95% CI [−334.
09, −56.
77], P < .
001), borderline premature beat (MD = −42.
92, 95% CI [−77.
18, −8.
67], P = .
01), short-burst ventricular tachycardia (MD = −35.
98, 95% CI [−39.
66, −32.
30], P < .
001), ST segment reduction (MD = −0.
47, 95% CI [−0.
54, −0.
40], P < .
001), ST segment decrease duration (MD = −0.
76, 95% CI [−0.
95, −0.
57], P < .
001).
However, no significant differences were observed in adverse reactions (OR = 0.
54, 95% CI [0.
27, 1.
09], P = .
09).
Conclusion: Compared to metoprolol alone, WXG and metoprolol can more effectively manage patients with CHD and arrhythmia.
However, additional large-scale, multicenter, rigorous, and high-quality randomized controlled trials are warranted to verify the present findings.

Related Results

Effect of WenXin KeLi on Improvement of Arrhythmia after Myocardial Infarction by Intervening PI3K-AKT-mTOR Autophagy Pathway
Effect of WenXin KeLi on Improvement of Arrhythmia after Myocardial Infarction by Intervening PI3K-AKT-mTOR Autophagy Pathway
Background. Myocardial infarction (MI) is an acute and serious cardiovascular disease. Arrhythmia after MI can lead to sudden cardiac death, which seriously affects the survival ou...
e0680 Relationship between polymorphism of ACE and the curative effect of metoprolol on chronic heart failure
e0680 Relationship between polymorphism of ACE and the curative effect of metoprolol on chronic heart failure
Objective To investigate the effect of metoprolol on chronic heart failure and to discuss the relationship between polymorphism of ACE and the curative effect of ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Early Onset of Coronary Subclavian Steal Syndrome: A Case Report and Literature Review
Early Onset of Coronary Subclavian Steal Syndrome: A Case Report and Literature Review
Abstract Introduction Coronary subclavian steal syndrome (CSSS) is a rare phenomenon that often goes undiagnosed and causes severe complications, including death. This report prese...
e0379 Study of correlationship between myeloperoxidase paraoxonase and coron
e0379 Study of correlationship between myeloperoxidase paraoxonase and coron
Objective To investigate the clinical significance of myeloperoxidase (MPO)and paraoxonase (PON1) in coronary heart disease (CHD). ...

Back to Top